RE: Here we go1 May 2020 09:21
22nd April RNA
Using its humanized mice, the Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), which were developed
to model blood and autoimmune diseases and to test treatments, Hemogenyx will seek to discover human neutralizing
antibodies - antibodies that are typically developed by the human immune system to neutralize invading viral pathogens - that could be used to fight SARS-CoV-2 (the virus that causes COVID-19) infections.
Prior to the appearance of COVID-19, Hemogenyx had been working independently and with a number of pharmaceutical company partners to utilize the exceptional features of ApbHC to identify and isolate human neutralizing antibodies
for use as antiviral therapies. The Company's methodology is generally applicable to new pathogens including viruses,
as previously described in the Company's original announcement of the development of ApbHC.